<DOC>
	<DOCNO>NCT01458171</DOCNO>
	<brief_summary>The objective study ass long-term safety , tolerability , efficacy IgPro20 subject primary immunodeficiency ( PID ) follow-up pivotal study ZLB06_002CR ( NCT01199705 ) .</brief_summary>
	<brief_title>Follow-up Study Subcutaneous Immune Globulin Patients Requiring IgG Replacement Therapy ( Japan Study )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Subjects participate study ZLB06_002CR tolerate IgPro20 well . Written inform consent subject/parent/legally acceptable representative . Written assent underage subject ( â‰¥7 year time obtain informed consent ) , far possible . Ongoing serious bacterial infection ( SBIs ) ( pneumonia , bacteremia/septicemia , osteomyelitis/septic arthritis , bacterial meningitis , visceral abscess ) time first infusion . Hypoalbuminemia , proteinlosing enteropathy , proteinuria ( know total urine protein concentration &gt; 0.2 g/L urine protein ++ dipstick ) . Pregnancy nurse mother . Participation study investigational medicinal product ( IMP ) within 3 month prior enrollment except ZLB06_002CR . Subjects plan donate blood study . Reentry subject previously participate current followup study . Known suspect antibody IMP , excipients IMP .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Immune globulin subcutaneous</keyword>
	<keyword>SCIG</keyword>
	<keyword>Primary immunodeficiency</keyword>
	<keyword>PID</keyword>
</DOC>